{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:54:26Z","timestamp":1777596866048,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.humpath.2016.10.015","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T01:30:23Z","timestamp":1478223023000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer"],"prefix":"10.1016","volume":"60","author":[{"given":"Yao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-8515","authenticated-orcid":false,"given":"Ge","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.10.015_bb0005","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2016.10.015_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.humpath.2016.10.015_bb0015","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin"},{"key":"10.1016\/j.humpath.2016.10.015_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2013.00251","article-title":"Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment","volume":"3","author":"Chien","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2016.10.015_bb0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2009.11.033","article-title":"Achievements and unmet needs in the management of advanced ovarian cancer","volume":"117","author":"Guarneri","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.humpath.2016.10.015_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1525-1438.2005.15351.x","article-title":"Treatment goals in ovarian cancer","volume":"15","author":"Ozols","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2016.10.015_bb0035","doi-asserted-by":"crossref","first-page":"26172","DOI":"10.1074\/jbc.M001323200","article-title":"Functional cloning and characterization of a novel nonhomeodomain protein that inhibits the binding of PBX1-HOX complexes to DNA","volume":"275","author":"Abramovich","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2016.10.015_bb0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.biopha.2015.12.012","article-title":"HPIP promotes non\u2013small cell lung cancer cell proliferation, migration and invasion through regulation of the Sonic hedgehog signaling pathway","volume":"77","author":"Pan","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.humpath.2016.10.015_bb0045","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1007\/s13277-015-4453-4","article-title":"The involvement of hematopoietic pre\u2013B cell leukemia transcription factor-interacting protein in regulating epithelial-mesenchymal transition of human spinal glioblastoma","volume":"37","author":"Wang","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.humpath.2016.10.015_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biopha.2015.08.027","article-title":"HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K\/AKT signaling pathway","volume":"75","author":"Wang","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.humpath.2016.10.015_bb0055","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/cas.12754","article-title":"Hematopoietic pre\u2013B cell leukemia transcription factor interacting protein is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, migration, and invasion","volume":"106","author":"Feng","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2016.10.015_bb0060","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1038\/srep09429","article-title":"HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion","volume":"5","author":"Feng","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2016.10.015_bb0065","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1038\/onc.2014.389","article-title":"Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics","volume":"34","author":"Bugide","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2016.10.015_bb0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jop.12210","article-title":"Potential role of hematopoietic pre\u2013B-cell leukemia transcription factor\u2013interacting protein in oral carcinogenesis","volume":"44","author":"Okada","year":"2015","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.humpath.2016.10.015_bb0075","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/iub.1202","article-title":"HPIP is upregulated in liver cancer and promotes hepatoma cell proliferation via activation of G2\/M transition","volume":"65","author":"Xu","year":"2013","journal-title":"IUBMB Life"},{"key":"10.1016\/j.humpath.2016.10.015_bb0080","first-page":"4349","article-title":"Reduced heterochromatin protein 1-beta (HP1beta) expression is correlated with increased invasive activity in human melanoma cells","volume":"26","author":"Nishimura","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.humpath.2016.10.015_bb0085","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/cdd.2014.2","article-title":"MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation","volume":"21","author":"Shostak","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.humpath.2016.10.015_bb0090","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.bbamcr.2008.01.026","article-title":"The estrogen receptor\u2013interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT","volume":"1783","author":"Wang","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.humpath.2016.10.015_bb0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.humpath.2016.10.015_bb0100","series-title":"WHO Classification of Tumours, Pathology and Genetics: Tumours of the Breast and Female Genital Organs","author":"Tavassoeli","year":"2003"},{"key":"10.1016\/j.humpath.2016.10.015_bb0105","article-title":"Ovarian cancer including fallopian tube cancer and primary peritoneal cancer","author":"Morgan","year":"2009","journal-title":"NCCN Clin Pract Guidel Oncol"},{"key":"10.1016\/j.humpath.2016.10.015_bb0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2016.10.015_bb0115","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.acthis.2015.08.005","article-title":"The relationship between estrogen receptors and microtubule dynamics in post-menopausal rat brain","volume":"117","author":"Selina","year":"2015","journal-title":"Acta Histochem"},{"key":"10.1016\/j.humpath.2016.10.015_bb0120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1210\/me.2011-1263","article-title":"TEX11 modulates germ cell proliferation by competing with estrogen receptor beta for the binding to HPIP","volume":"26","author":"Yu","year":"2012","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.humpath.2016.10.015_bb0125","first-page":"630","article-title":"Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis","volume":"123","author":"Xu","year":"2013","journal-title":"J Clin Invest"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:20:24Z","timestamp":1718878824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716302866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":25,"alternative-id":["S0046817716302866"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.10.015","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}